BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis

Mean incremental net monetary benefit




Figure S1 Mean incremental net monetary benefit (iNMB) for tapering csDMARDs minus tapering TNF-inhibitors first. Results are plotted against different levels of willingness to pay (WTP) per quality adjusted life year (QALY), and with 95% confidence intervals. The iNMB was calculated as the incremental benefit times different levels of WTP, minus the incremental costs. csDMARDs: conventional synthetic DMARDs; iNMB: incremental net monetary benefit; QALY: quality adjusted life year; WTP: willingness to pay.